This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of -33.33% and 24.31%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
by Zacks Equity Research
Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 13.83% and 5.52%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
by Zacks Equity Research
The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
by Zacks Equity Research
Avid Bioservices (CDMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
by Zacks Equity Research
Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.
Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View
by Zacks Equity Research
Novavax (NVAX) reports better-than-expected third-quarter results, with earnings and revenues beating estimates. It lowers product sales guidance for 2023.
Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.
Avid Bioservices (CDMO) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 100% and 10.96%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of -1,171.43% and 8.80%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?
Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 46.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 7.14% and 3.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of -6.15% and 162.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 275% and 5.61%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Steer Clear Of These 4 Toxic Stocks to Avoid Losses
by Rimmi Singhi
Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.
Lumos Pharma (LUMO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of -3.16% and 48.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 433.33% and 8.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Evogene (EVGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 20% and 79.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -4.17% and 31.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines, Inc. (VBIV) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -12.50% and 75.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of 10.69% and 15.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?